Just before the outbreak, the NIAID, headed by Dr. Fauci, funded a grant for monkeypox treatment research, especially tecovirimat.
- MAJOR PEER REVIEWED STUDY: Moderna Vaccine Increases Myocarditis Risk By 44 Times In Young Adults
- MUST READ: High Level International Bankers Simulate The Collapse Of Global Financial System
- BIG STORY: Wuhan Lab Isolated Monkeypox Strain In 2020
- EXPLOSIVE: Ukraine Biolabs Used Fever Carrying Mosquitoes To Spark Dengue Pandemic In Cuba
Shortly before the virus spread in a global outbreak, Anthony Fauci’s National Institutes of Health organization was sponsoring research to find treatments for monkeypox.
The National Institute of Allergy and Infectious Diseases (NIAID), which Fauci heads, has previously been criticized for sponsoring bat coronavirus research at the Wuhan Institute of Virology, which many public health professionals and intelligence officials believe is the source of COVID-19.
Shortly before the viral disease spread in a global outbreak, the NIAID financed research into potential cures for monkeypox. The NIAID grant comes at a time when pharmaceutical companies like Pfizer and Johnson & Johnson are reaping record profits as a result of the COVID-19 outbreak.
“A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease,” according to the grant.
Subscribe to GreatGameIndia
“The funding supports a clinical trial to identify effective treatments for monkeypox virus disease,” according to a summary of the study, which has yet to produce any publicly available studies, articles, or patents despite starting in September 2020.
“The similarity between monkeypox and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries,” adds the grant summary.
In 2021, the National Institutes of Health (NIH) awarded $9,824,009 to Leidos Biomedical Research, which operates Frederick National Laboratory for Cancer Research in collaboration with the NIH’s National Cancer Institute (NCI).
Lori Dodd, who works as a Mathematical Statistician at the NIAID’s Biostatistics Research Branch, was awarded the grant, which will end on September 27th, 2025.
Dodd was previously exposed for her role in the NIAID’s cover-up of the agency allegedly changing the endpoint in a trial investigating the effects of remdesivir against COVID-19 in order to make it appear more effective.